Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Fibromyalgia
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Fibromyalgia
    Milnacipran Improves Core Symptoms of Fibromyalgia Syndrome: Presented at ECNP - (DGDispatch)
    TopAbstracts in Fibromyalgia 08/27/2008 - (DGNews)
    Pregabalin Safely Treats Fibromyalgia Pain for Up to 1 Year: Presented at WCP - (DGDispatch)
    Pivotal Studies Show Milnacipran Reduces Fibromyalgia Pain: Presented at WCP - (DGDispatch)
    TopAbstracts in Fibromyalgia 07/30/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Fibromyalgia

    Webcasts/CME archive

     Recent cases - Fibromyalgia
      Evaluation of the Patient with Pain All Over

      Cases archive
        




      my personal edition > fibromyalgia > news
      divider

        E-Mail this DGNews to a colleague

      DGNews


      FDA Approves Duloxetine HCl for the Management of Fibromyalgia

        NEW YORK -- June 16, 2008 -- The US Food and Drug Administration (FDA) has approved duloxetine HCl (Cymbalta) for the management of fibromyalgia, a chronic widespread pain disorder. Duloxetine HCl is a serotonin-norepinephrine reuptake inhibitor indicated to reduce pain in patients with fibromyalgia.

        Duloxetine HCl was proven efficacious in 3 pivotal 3-month clinical trials involving 874 patients with fibromyalgia. In both studies, duloxetine HCl reduced pain at the study's endpoint compared with placebo as measured by the Brief Pain Inventory (BPI) 24-hour average pain scale.

        Significant improvement in pain for duloxetine HCl versus placebo was observed in the first week of each study. Fifty-one percent and 55% of patients on duloxetine HCl had a 30% improvement on the BPI at the study's endpoint. In addition, 65% and 66% of patients taking duloxetine HCl 60 mg daily reported feeling better at the study's endpoint as measured by the Patient Global Impression of Improvement (PGI-I). Duloxetine HCl 60 mg was also superior to placebo on the Fibromyalgia Impact Questionnaire Total Score.

        In 4 pooled studies, the most commonly observed adverse events in duloxetine HCl-treated patients with fibromyalgia were nausea, dry mouth, constipation, decreased appetite, sleepiness, increased sweating, and agitation. In the placebo-controlled clinical trials, the overall discontinuation rates due to adverse events for duloxetine HCl versus placebo were 20% and 12%, respectively.

        The approval marks the fourth disorder that the FDA has approved for duloxetine HCl. In addition to fibromyalgia, duloxetine HCl is approved for the management of diabetic peripheral neuropathic pain (DPNP) and the treatment of major depressive disorder and generalised anxiety disorder, all in adults aged 18 years and older.


        SOURCE: Chamberlain Healthcare Public Relations




      E-Mail this DGNews to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send